rTMS on Appetite and Cognitive Function in Schizophrenia
Repetitive Transcranial Magnetic Stimulation on Appetite and Cognitive Function in Schizophrenia
1 other identifier
interventional
10
1 country
1
Brief Summary
The weight gain and metabolic dysfunction has been vital conditions for individuals with schizophrenia. rTMS is a promising novel intervention, which have strong potentials on moderating increased appetite and cognitive deficits in schizophrenia, as it has been proved for the treatment of depression. Therefore, the investigators designed this randomized controlled clinical trial to evaluate the efficacy and safety of rTMS, using iTBS pattern, on prevention and treatment for elevated appetite and cognitive deficiency in individual with schizophrenia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable schizophrenia
Started Apr 2021
Shorter than P25 for not_applicable schizophrenia
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 13, 2021
CompletedFirst Posted
Study publicly available on registry
January 20, 2021
CompletedStudy Start
First participant enrolled
April 20, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2022
CompletedNovember 16, 2022
November 1, 2022
1.5 years
January 13, 2021
November 14, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Change of Appetite
Three-Factor Eating Questionnaire
Change from Baseline to 6days and 36days
Change of MCCB
The MATRICS™ Consensus Cognitive Battery
Change from Baseline to 6days and 36days
Change of ERP
Food picture ERP recorded by EEG
Change from Baseline to 6days and 36days
Secondary Outcomes (7)
Change of fasting glucose
Change from Baseline to 6days and 36days
Change of fasting insulin level
Change from Baseline to 6days and 36days
Change of Triglyceride
Change from Baseline to 6days and 36days
Change of Total Cholesterol
Change from Baseline to 6days and 36days
Change of LDL
Change from Baseline to 6days and 36days
- +2 more secondary outcomes
Study Arms (2)
iTBS stimulation
EXPERIMENTALThe participants randomized into experimental group will receive iTBS stimulation of dlPFC 5 times a day, with 1h interval between two stimulations, and for 5 continuous days.
Sham stimulation
SHAM COMPARATORThe participants randomized intoSham group will receive Sham stimulation, as the coil vertical to the brain surface, 5 times a day, with 1h interval between two stimulations, and for 5 continuous days.
Interventions
Intermittent theta burst stimulation (iTBS) on left dlPFC. 90% RMT, 50Hz within train and 5Hz train for 2 second and rest for 8 second. 600 train and 200 second in total.
TMS coil vertical to the brain surface, with same protocol as iTBS
Eligibility Criteria
You may qualify if:
- Patients with schizophrenia in accordance with DSM-5
- Commorbid with significant weight gain after antipsychotics
- Informed Consent
You may not qualify if:
- Diagnosed with other mental disease in accordance with DSM-5
- Comorbid with other severe physiological disease
- Used antipsychotic, antidepressants, mood stabilizer, or other psychoactive substances before
- Drug or alcohol abuse
- Pregnant or lactating
- Contraindication to rTMS
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Central South Universitylead
- Shanghai Mental Health Centercollaborator
Study Sites (1)
Central South University
Changsha, Hunan, 410000, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Renrong Wu, Prof
Central South University Psychiatry Department
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
January 13, 2021
First Posted
January 20, 2021
Study Start
April 20, 2021
Primary Completion
November 1, 2022
Study Completion
December 1, 2022
Last Updated
November 16, 2022
Record last verified: 2022-11
Data Sharing
- IPD Sharing
- Will not share